<italic style="font-style: italic">NRAS</italic>突变型晚期黑色素瘤的治疗进展

赵博伦; 朱冠男

doi:10.19401/j.cnki.1007-3639.2023.10.006

您当前的位置：

首页 >

文章列表页 >

NRAS突变型晚期黑色素瘤的治疗进展

综述 | 更新时间：2025-12-31

- NRAS突变型晚期黑色素瘤的治疗进展
- Advances in the treatment of advanced melanoma with NRAS gene mutation
- 中国癌症杂志 2023年33卷第10期页码：936-944
- 作者机构：
  
  空军军医大学西京医院皮肤科，陕西西安 710032
- 作者简介：
  
  [ "赵博伦（ORCID: 0000-0003-0326-459X），硕士研究生在读。" ]
  朱冠男（ORCID: 0000-0002-2980-0074），博士，副主任医师，空军军医大学西京医院皮肤科主任。
- 基金信息：
  
  国家自然科学基金(82172607);国家自然科学基金(81702714)
- DOI：10.19401/j.cnki.1007-3639.2023.10.006
  中图分类号： R739.5
- 收稿：2023-05-16，
  
  修回：2023-10-01，
  
  纸质出版：2023-10-30
- 稿件说明：
移动端阅览
赵博伦, 朱冠男. NRAS突变型晚期黑色素瘤的治疗进展[J]. 中国癌症杂志, 2023,33(10):936-944.

Bolun ZHAO, Guannan ZHU. Advances in the treatment of advanced melanoma with NRAS gene mutation[J]. China Oncology, 2023, 33(10): 936-944.
赵博伦, 朱冠男. NRAS突变型晚期黑色素瘤的治疗进展[J]. 中国癌症杂志, 2023,33(10):936-944. DOI： 10.19401/j.cnki.1007-3639.2023.10.006.

Bolun ZHAO, Guannan ZHU. Advances in the treatment of advanced melanoma with NRAS gene mutation[J]. China Oncology, 2023, 33(10): 936-944. DOI： 10.19401/j.cnki.1007-3639.2023.10.006.

摘要

黑色素瘤的发生、发展与多种癌基因的激活密切相关。15%~20%的黑色素瘤患者存在

NRAS

基因的激活突变，携带该突变基因的黑色素瘤具有更强的侵袭性，治疗难度大。由于RAS蛋白突变位点属于弱药物靶标，目前尚缺乏有效的靶向抑制剂，因此临床上多以免疫检查点抑制剂作为

NRAS

突变型晚期黑色素瘤的一线治疗方案，然而治疗反应率较低。近年来，在

NRAS

突变亚型中靶向治疗方案的探索主要集中在

NRAS

下游丝裂原活化蛋白激酶（mitogen-activated protein kinase，MAPK）通路，但结果不一：新型MEK1/2抑制剂tunlametinib，在晚期

NRAS

突变患者中总体客观缓解率（objective response rate，ORR）达到34.7%，较既往的binimetinib显著提高；然而泛RAF抑制剂belvarafenib和ERK抑制剂ulixertinib的Ⅰ期临床试验却未能展示出该药明显的优势。此外，以MEK抑制剂为基础的联合治疗也取得一定进展，现有证据表明，分子抑制剂类药物较免疫检查点抑制剂显示出更多的优势：选择性BRAF/CRAF抑制剂naporafenib（LXH254）与MEK抑制剂trametinib联合治疗

NRAS

突变型黑色素瘤的Ⅰb期临床试验中ORR达到46.7%；细胞周期蛋白依赖性激酶4/6（cyclin-dependent kinase4/6，CDK4/6）抑制剂ribociclib和binimetinib联合治疗在携带

NRAS

突变同时合并细胞周期蛋白基因异常的人群中可达32.5%；黏着斑激酶（focal adhesion kinase，FAK）抑制剂IN10018联合cobimetinib的研究结果也表现出较好的ORR（38.5%）；但免疫检查点抑制剂程序性死亡[蛋白

]

配体-1（programmed death ligand-1，PD-L1）单抗durvalumab联合trametinib方案仅使27.2%的患者达到部分缓解（3/11）。与此同时，部分临床前研究结果也显示出一些转化潜质：如热激蛋白90（heat shock

protein 90，HSP90）抑制剂XL888和丝氨酸/苏氨酸蛋白激酶19（serine/threonine protein kinase 19，STK19）抑制剂均在动物模型中表现出显著抑制

NRAS

突变型黑色素瘤细胞生长的能力。本文综述了

NRAS

突变型黑色素瘤的致癌机制及近年来治疗领域的研究进展，旨在展示该亚型患者的治疗现状，对多种新型治疗方法的临床研究结果进行总结和归纳，为当前临床实践和未来联合治疗方案提供依据。

Abstract

Oncogenic mutations are responsible for a majority of the malignancy of melanoma. Activating mutations of

NRAS

gene are found in 15%-20% melanoma cases

endowing the tumor cells with more aggressive phenotypes and greater difficulty to treat. The development of targeted inhibitor of mutant

NRAS

remains a big challenge since the mutation sites could hardly be druggable. Therefore

immune checkpoint inhibitors are currently recommended as the first-line therapy for

NRAS

mutant advanced melanoma albeit the response rate is still far from satisfaction. In recent years

the exploration of targeted therapy regimens has focused on the downstream pathway of

NRAS

the mitogen-activated protein kinase (MAPK) pathway. A novel MEK1/2 inhibitor tunlametinib was reported to achieve an objective response rate (ORR) of 34.7% which is higher than the ORR of binimetinib in previous report. However

the phase Ⅰ trial of the pan-RAF inhibitor belvarafenib and the ERK inhibitor ulixertinib failed to show marked benefits. In the meanwhile

MEK inhibitor-based combination therapy has also achieved some progress: it was reported in the phase Ⅰb trial of the selective BRAF/CRAF inhibitor naporafenib (LXH254) combined with Trametinib in

NRAS

mutant melanoma that the ORR was 46.7%. The ORR of binetinib plus the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor

ribociclib

was 32.5% in patients with NRAS mutation with concurrent alterations of CDKN2A

CDK4

or CCND1. The response rate of the combination of focal adhesion kinase (FAK) inhibitor

IN10018

and cobimetinib was 38.5%. On the other hand

only 27.2% of patients carrying

NRAS mutation responded partially to the combined regimen of immune checkpoint inhibitor programmed death ligand-1 (PD-L1) monoclonal antibody durvalumab+trametinib. In addition

some preclinical findings have also shown translational potentials: for example

heat shock protein 90 (HSP90) inhibitor XL888 and serine/threonine protein kinase 19 (STK19) inhibitors were found to inhibit the growth of NRAS mutant melanoma in animal models. This article reviewed the oncogenic roles of NRAS mutation in melanoma and the cutting-edge clinical trials for the treatment of NRAS mutant melanoma

aiming to provide alterative treatment options for clinical practice and inspire novel combination regimen.

关键词

Keywords

references

TSAI F D , LOPES M S , ZHOU M , et al. KRAS 4A splice variant is widely expressed in cancer and uses a hybrid membrane-t argeting motif [J ] . Proc Natl Acad Sci U S A , 2015 , 112 ( 3 ): 779 - 784 . DOI: 10.1073/pnas.1412811112 http://doi.org/10.1073/pnas.1412811112 https://pnas.org/doi/full/10.1073/pnas.1412811112 https://pnas.org/doi/full/10.1073/pnas.1412811112

MACARA I G . The ras superfamily of molecular switches [J ] . Cell Signal , 1991 , 3 ( 3 ): 179 - 187 .

JAKOB J A , BASSETT R L Jr , NG C S , et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma [J ] . Cancer , 2012 , 118 ( 16 ): 4014 - 4023 . DOI: 10.1002/cncr.26724 http://doi.org/10.1002/cncr.26724 https://onlinelibrary.wiley.com/doi/10.1002/cncr.26724 https://onlinelibrary.wiley.com/doi/10.1002/cncr.26724

曾颖 , 康晓静 , 张祥月 , 等 . 肢端型黑素瘤 NRAS 基因突变检测及预后分析 [J ] . 中华皮肤科杂志 , 2016 , 49 ( 7 ): 474 - 477 .

LALLY S E , MILMAN T , ORLOFF M , et al. Mutational landscape and outcomes of conjunctival melanoma in 101 patients [J ] . Ophthalmology , 2022 , 129 ( 6 ): 679 - 693 . DOI: 10.1016/j.ophtha.2022.01.016 http://doi.org/10.1016/j.ophtha.2022.01.016 https://linkinghub.elsevier.com/retrieve/pii/S0161642022000689 https://linkinghub.elsevier.com/retrieve/pii/S0161642022000689

LISZKAY G , MÁTRAI Z , CZIRBESZ K , et al. Predictive and prognostic value of BRAF and NRAS mutation of 159 sentinel lymph node cases in melanoma-a retrospective single-institute study [J ] . Cancers (Basel) , 2021 , 13 ( 13 ): 3302 . DOI: 10.3390/cancers13133302 http://doi.org/10.3390/cancers13133302 https://www.mdpi.com/2072-6694/13/13/3302 https://www.mdpi.com/2072-6694/13/13/3302

ZABLOCKA T , KREISMANE M , PJANOVA D , et al. Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma [J ] . Oncol Lett , 2023 , 25 ( 1 ): 27 . DOI: 10.3892/ol http://doi.org/10.3892/ol http://www.spandidos-publications.com/10.3892/ol/ http://www.spandidos-publications.com/10.3892/ol/

DUMAZ N , HAYWARD R , MARTIN J , et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling [J ] . Cancer Res , 2006 , 66 ( 19 ): 9483 - 9491 . DOI: 10.1158/0008-5472.CAN-05-4227 http://doi.org/10.1158/0008-5472.CAN-05-4227 https://aacrjournals.org/cancerres/article/66/19/9483/526271/In-Melanoma-RAS-Mutations-Are-Accompanied-by https://aacrjournals.org/cancerres/article/66/19/9483/526271/In-Melanoma-RAS-Mutations-Are-Accompanied-by

PHADKE M S , SMALLEY K S M . Targeting NRAS mutations in advanced melanoma [J ] . J Clin Oncol , 2023 , 41 ( 14 ): 2661 - 2664 .

SMALLEY K S , HAASS N K , BRAFFORD P A , et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases [J ] . Mol Cancer Ther , 2006 , 5 ( 5 ): 1136 - 1144 .

SHARMA A , TRIVEDI N R , ZIMMERMAN M A , et al. Mutant V599EB- Raf regulates growth and vascular development of malignant melanoma tumors [J ] . Cancer Res , 2005 , 65 ( 6 ): 2412 - 2421 . DOI: 10.1158/0008-5472.CAN-04-2423 http://doi.org/10.1158/0008-5472.CAN-04-2423 https://aacrjournals.org/cancerres/article/65/6/2412/519053/Mutant-V599EB-Raf-Regulates-Growth-and-Vascular https://aacrjournals.org/cancerres/article/65/6/2412/519053/Mutant-V599EB-Raf-Regulates-Growth-and-Vascular

SATYAMOORTHY K , LI G , GERRERO M R , et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation [J ] . Cancer Res , 2003 , 63 ( 4 ): 756 - 759 .

ZHUANG L , LEE C S , SCOLYER R A , et al. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma [J ] . J Clin Pathol , 2005 , 58 ( 11 ): 1163 - 1169 . DOI: 10.1136/jcp.2005.025957 http://doi.org/10.1136/jcp.2005.025957

OBA J , NAKAHARA T , ABE T , et al. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value [J ] . J Dermatol Sci , 2011 , 62 ( 2 ): 116 - 123 . DOI: 10.1016/j.jdermsci.2011.02.011 http://doi.org/10.1016/j.jdermsci.2011.02.011

CANCER GENOME ATLAS NETWORK . Genomic classification of cutaneous melanoma [J ] . Cell , 2015 , 161 ( 7 ): 1681 - 1696 . DOI: 10.1016/j.cell.2015.05.044 http://doi.org/10.1016/j.cell.2015.05.044

ROBERTSON G P . Functional and therapeutic significance of Akt deregulation in malignant melanoma [J ] . Cancer Metastasis Rev , 2005 , 24 ( 2 ): 273 - 285 . DOI: 10.1007/s10555-005-1577-9 http://doi.org/10.1007/s10555-005-1577-9 http://link.springer.com/10.1007/s10555-005-1577-9 http://link.springer.com/10.1007/s10555-005-1577-9

XIE X Q , WHITE E P , MEHNERT J M . Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma [J ] . PLoS One , 2013 , 8 ( 1 ): e55096 . DOI: 10.1371/journal.pone.0055096 http://doi.org/10.1371/journal.pone.0055096 https://dx.plos.org/10.1371/journal.pone.0055096 https://dx.plos.org/10.1371/journal.pone.0055096

ZIPFEL P A , BRADY D C , KASHATUS D F , et al. Ral activation promotes melanomagenesis [J ] . Oncogene , 2010 , 29 ( 34 ): 4859 - 4864 . DOI: 10.1038/onc.2010.224 http://doi.org/10.1038/onc.2010.224

MISHRA P J , HA L , RIEKER J , et al. Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation [J ] . Oncogene , 2010 , 29 ( 16 ): 2449 - 2456 . DOI: 10.1038/onc.2009.521 http://doi.org/10.1038/onc.2009.521

FALSETTI S C , WANG D A , PENG H R , et al. Geranylgeranyltransferase Ⅰ inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth [J ] . Mol Cell Biol , 2007 , 27 ( 22 ): 8003 - 8014 . DOI: 10.1128/MCB.00057-07 http://doi.org/10.1128/MCB.00057-07 https://www.tandfonline.com/doi/full/10.1128/MCB.00057-07 https://www.tandfonline.com/doi/full/10.1128/MCB.00057-07

SINGHAL S S , AWASTHI Y C , AWASTHI S . Regression of melanoma in a murine model by RLIP76 depletion [J ] . Cancer Res , 2006 , 66 ( 4 ): 2354 - 2360 .

MARTÍN M T , ALCALDE M , PLOU F J , et al. Covalent immobilization of cyclodextrin glucosyltransferase (CGTase) in activated silica and Sepharose [J ] . Indian J Biochem Biophys , 2002 , 39 ( 4 ): 229 - 234 .

SWETTER S M , THOMPSON J A , ALBERTINI M R , et al. NCCN guidelines® insights: melanoma: cutaneous, version 2.2021 [J ] . J Natl Compr Canc Netw , 2021 , 19 ( 4 ): 364 - 376 . DOI: 10.6004/jnccn.2021.0018 http://doi.org/10.6004/jnccn.2021.0018 https://jnccn.org/view/journals/jnccn/19/4/article-p364.xml https://jnccn.org/view/journals/jnccn/19/4/article-p364.xml

MICHIELIN O , VAN AKKOOI A C J , ASCIERTO P A , et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2019 , 30 ( 12 ): 1884 - 1901 . DOI: S0923-7534(20)32563-1 http://doi.org/S0923-7534(20)32563-1

JAEGER Z J , RAVAL N S , MAVERAKIS N K A , et al. Objective response to immune checkpoint inhibitor therapy in NRAS -mutant melanoma: a systematic review and meta-analysis [J ] . Front Med (Lausanne) , 2023 , 10 : 1090737 .

ZHOU L , WANG X , CHI Z H , et al. Association of NRAS mutation with clinical outcomes of anti-PD-1 monotherapy in advanced melanoma: a pooled analysis of four Asian clinical trials [J ] . Front Immunol , 2021 , 12 : 691032 . DOI: 10.3389/fimmu.2021.691032 http://doi.org/10.3389/fimmu.2021.691032 https://www.frontiersin.org/articles/10.3389/fimmu.2021.691032/full https://www.frontiersin.org/articles/10.3389/fimmu.2021.691032/full

DUMMER R , SCHADENDORF D , ASCIERTO P A , et al. Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial [J ] . Lancet Oncol , 2017 , 18 ( 4 ): 435 - 445 . DOI: 10.1016/S1470-2045(17)30180-8 http://doi.org/10.1016/S1470-2045(17)30180-8 https://linkinghub.elsevier.com/retrieve/pii/S1470204517301808 https://linkinghub.elsevier.com/retrieve/pii/S1470204517301808

LEBBÉ C , DUTRIAUX C , LESIMPLE T , et al. Pimasertib versus dacarbazine in patients with unresectable NRAS -mutated cutaneous melanoma: phase Ⅱ, randomized, controlled trial with crossover [J ] . Cancers (Basel) , 2020 , 12 ( 7 ): 1727 . DOI: 10.3390/cancers12071727 http://doi.org/10.3390/cancers12071727 https://www.mdpi.com/2072-6694/12/7/1727 https://www.mdpi.com/2072-6694/12/7/1727

RYAN M B , CORCORAN R B . Therapeutic strategies to target RAS-mutant cancers [J ] . Nat Rev Clin Oncol , 2018 , 15 ( 11 ): 709 - 720 . DOI: 10.1038/s41571-018-0105-0 http://doi.org/10.1038/s41571-018-0105-0

GAJEWSKI T F , SALAMA A K S , NIEDZWIECKI D , et al. Phase Ⅱ study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) [J ] . J Transl Med , 2012 , 10 : 246 . DOI: 10.1186/1479-5876-10-246 http://doi.org/10.1186/1479-5876-10-246

FEDORENKO I V , GIBNEY G T , SMALLEY K M . NRAS mutant melanoma: biological behavior and future strategies for therapeutic management [J ] . Oncogene , 2013 , 32 ( 25 ): 3009 - 3018 . DOI: 10.1038/onc.2012.453 http://doi.org/10.1038/onc.2012.453

TATEISHI K , TSUBAKI M , TAKEDA T , et al. FTI-277 and GGTI-289 induce apoptosis via inhibition of the Ras/ERK and Ras/mTOR pathway in head and neck carcinoma HEp-2 and HSC-3 cells [J ] . J BUON , 2021 , 26 ( 2 ): 606 - 612 .

SKOULIDIS F , LI B T , DY G K , et al. Sotorasib for lung cancers with KRAS p. G12 C mutation [J ] . N Engl J Med , 2021 , 384 ( 25 ): 2371 - 2381 . DOI: 10.1056/NEJMoa2103695 http://doi.org/10.1056/NEJMoa2103695 http://www.nejm.org/doi/10.1056/NEJMoa2103695 http://www.nejm.org/doi/10.1056/NEJMoa2103695

HONG D S , FAKIH M G , STRICKLER J H , et al. KRAS G12 C inhibition with sotorasib in advanced solid tumors [J ] . N Engl J Med , 2020 , 383 ( 13 ): 1207 - 1217 . DOI: 10.1056/NEJMoa1917239 http://doi.org/10.1056/NEJMoa1917239 http://www.nejm.org/doi/10.1056/NEJMoa1917239 http://www.nejm.org/doi/10.1056/NEJMoa1917239

JAISWAL B S , JANAKIRAMAN V , KLJAVIN N M , et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors [J ] . PLoS One , 2009 , 4 ( 5 ): e5717 . DOI: 10.1371/journal.pone.0005717 http://doi.org/10.1371/journal.pone.0005717 https://dx.plos.org/10.1371/journal.pone.0005717 https://dx.plos.org/10.1371/journal.pone.0005717

YEN I , SHANAHAN F , LEE J , et al. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma [J ] . Nature , 2021 , 594 ( 7863 ): 418 - 423 . DOI: 10.1038/s41586-021-03515-1 http://doi.org/10.1038/s41586-021-03515-1

WANG X , LUO Z G , CHEN J , et al. First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations [J ] . BMC Med , 2023 , 21 ( 1 ): 2 . DOI: 10.1186/s12916-022-02669-7 http://doi.org/10.1186/s12916-022-02669-7

ADAM C , FUSI L , WEISS N , et al. Efficient suppression of NRAS -driven melanoma by Co-inhibition of ERK1/2 and ERK5 MAPK pathways [J ] . J Invest Dermatol , 2020 , 140 ( 12 ): 2455 - 2465 .e10. DOI: 10.1016/j.jid.2020.03.972 http://doi.org/10.1016/j.jid.2020.03.972 https://linkinghub.elsevier.com/retrieve/pii/S0022202X2031407X https://linkinghub.elsevier.com/retrieve/pii/S0022202X2031407X

CARLINO M S , TODD J R , GOWRISHANKAR K , et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma [J ] . Mol Oncol , 2014 , 8 ( 3 ): 544 - 554 . DOI: 10.1016/j.molonc.2014.01.003 http://doi.org/10.1016/j.molonc.2014.01.003 https://febs.onlinelibrary.wiley.com/doi/10.1016/j.molonc.2014.01.003 https://febs.onlinelibrary.wiley.com/doi/10.1016/j.molonc.2014.01.003

MENDZELEVSKI B , FERBER G , JANKU F , et al. Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies [J ] . Cancer Chemother Pharmacol , 2018 , 81 ( 6 ): 1129 - 1141 . DOI: 10.1007/s00280-018-3564-1 http://doi.org/10.1007/s00280-018-3564-1

ATEFI M , TITZ B , AVRAMIS E , et al. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma [J ] . Mol Cancer , 2015 , 14 ( 1 ): 27 . DOI: 10.1186/s12943-015-0293-5 http://doi.org/10.1186/s12943-015-0293-5 https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0293-5 https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0293-5

DE BRAUD F , DOOMS C , HEIST R S , et al. Initial evidence f or the efficacy of naporafenib in combination with trametinib in NRAS -mutant melanoma: results from the expansion arm of a phase ib, open-label study [J ] . J Clin Oncol , 2023 , 41 ( 14 ): 2651 - 2660 .

POSCH C , MOSLEHI H , FEENEY L , et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo [J ] . Proc Natl Acad Sci U S A , 2013 , 110 ( 10 ): 4015 - 4020 . DOI: 10.1073/pnas.1216013110 http://doi.org/10.1073/pnas.1216013110 https://pnas.org/doi/full/10.1073/pnas.1216013110 https://pnas.org/doi/full/10.1073/pnas.1216013110

JURIC D , SORIA J C , SHARMA S , et al. A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors [J ] . J Clin Oncol , 2014 , 32 ( 15_suppl ): 9051 . DOI: 10.1200/jco.2014.32.15_suppl.9051 http://doi.org/10.1200/jco.2014.32.15_suppl.9051 http://ascopubs.org/doi/10.1200/jco.2014.32.15_suppl.9051 http://ascopubs.org/doi/10.1200/jco.2014.32.15_suppl.9051

ALGAZI A P , ESTEVE-PUIG R , NOSRATI A , et al. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS -mutant and wild-type melanoma [J ] . Pigment Cell Melanoma Res , 2018 , 31 ( 1 ): 110 - 114 .

SCHULER M , ZIMMER L , KIM K B , et al. Phase Ⅰb/Ⅱ trial of ribociclib in combination with binimetinib in patients with NRAS -mutant melanoma [J ] . Clin Cancer Res , 2022 , 28 ( 14 ): 3002 - 3010 . DOI: 10.1158/1078-0432.CCR-21-3872 http://doi.org/10.1158/1078-0432.CCR-21-3872 https://aacrjournals.org/clincancerres/article/28/14/3002/706874/Phase-Ib-II-Trial-of-Ribociclib-in-Combination https://aacrjournals.org/clincancerres/article/28/14/3002/706874/Phase-Ib-II-Trial-of-Ribociclib-in-Combination

InxMed releases data demonstrating IN10018 therapeutic potential in patients with metastatic melanoma at SMR 2022 [R ] . SMR , October 17-20, 2022 (Abstract:141).

KINSEY C G , CAMOLOTTO S A , BOESPFLUG A M , et al. Protective autophagy elicited by RA F→MEK→ERK inhibition suggests a treatment strategy for RAS -driven cancers [J ] . Nat Med , 2019 , 25 ( 4 ): 620 - 627 . DOI: 10.1038/s41591-019-0367-9 http://doi.org/10.1038/s41591-019-0367-9

RIBAS A , ALGAZI A , ASCIERTO P A , et al. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma [J ] . Nat Commun , 2020 , 11 ( 1 ): 6262 . DOI: 10.1038/s41467-020-19810-w http://doi.org/10.1038/s41467-020-19810-w

GOGAS H , DRÉNO B , LARKIN J , et al. Cobimetinib plus atezolizumab in BRAF V600 wild-type melanoma: primary results from the randomized phase Ⅲ IMspire170 study [J ] . Ann Oncol , 2021 , 32 ( 3 ): 384 - 394 . DOI: 10.1016/j.annonc.2020.12.004 http://doi.org/10.1016/j.annonc.2020.12.004 https://linkinghub.elsevier.com/retrieve/pii/S092375342043203X https://linkinghub.elsevier.com/retrieve/pii/S092375342043203X

GAO X J , XUE D D , CHENG J J , et al. Inhibition of axl promotes the therapeutic effect of targeted inhibition of the PI3K/Akt pathway in NRAS mutant melanoma cells [J ] . J Oncol , 2022 , 2022 : 2946929 .

LI S , WU X , YAN X , et al. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis [J ] . J Immunother Cancer , 2022 , 10 ( 2 ): e004036 . DOI: 10.1136/jitc-2021-004036 http://doi.org/10.1136/jitc-2021-004036 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-004036 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-004036

PUZANOV I , SOSMAN J , SANTORO A , et al. Phase Ⅰ trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors [J ] . Invest New Drugs , 2015 , 33 ( 1 ): 159 - 168 . DOI: 10.1007/s10637-014-0167-5 http://doi.org/10.1007/s10637-014-0167-5 https://link.springer.com/10.1007/s10637-014-0167-5 https://link.springer.com/10.1007/s10637-014-0167-5

MAO L , GUO J , ZHU L , et al. A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS -mutant melanoma [J ] . Eur J Cancer , 2022 , 175 : 125 - 135 . DOI: 10.1016/j.ejca.2022.08.005 http://doi.org/10.1016/j.ejca.2022.08.005 https://linkinghub.elsevier.com/retrieve/pii/S0959804922004816 https://linkinghub.elsevier.com/retrieve/pii/S0959804922004816

HAARBERG H E , PARAISO K H , WOOD E , et al. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS -mutant melanoma [J ] . Mol Cancer Ther , 2013 , 12 ( 6 ): 901 - 912 . DOI: 10.1158/1535-7163.MCT-12-1003 http://doi.org/10.1158/1535-7163.MCT-12-1003 https://aacrjournals.org/mct/article/12/6/901/91643/Inhibition-of-Wee1-AKT-and-CDK4-Underlies-the https://aacrjournals.org/mct/article/12/6/901/91643/Inhibition-of-Wee1-AKT-and-CDK4-Underlies-the

QIAN L , CHEN K , WANG C H , et al. Targeting NRAS -mutant cancers with the selective STK19 kinase inhibitor chelidonine [J ] . Clin Cancer Res , 2020 , 26 ( 13 ): 3408 - 3419 . DOI: 10.1158/1078-0432.CCR-19-2604 http://doi.org/10.1158/1078-0432.CCR-19-2604 https://aacrjournals.org/clincancerres/article/26/13/3408/82552/Targeting-NRAS-Mutant-Cancers-with-the-Selective https://aacrjournals.org/clincancerres/article/26/13/3408/82552/Targeting-NRAS-Mutant-Cancers-with-the-Selective

浏览量

3948

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

着丝粒蛋白A驱动的染色体不稳定性与乳腺癌相关性研究的进展及展望：机制、预后及临床靶向治疗应用

靶向治疗及免疫治疗联合化疗为产AFP阳性结肠癌患者带来显著获益1例病例报告并文献复习

转移性结直肠癌三线治疗的研究现状及进展

卡瑞利珠单抗联合化疗及靶向治疗在复发、转移及初治晚期宫颈癌中的疗效与安全性分析：一项回顾性队列研究

端粒酶抑制剂BIBR1532联合自噬抑制剂CQ抑制黑色素瘤细胞生存的机制研究

NRAS突变型晚期黑色素瘤的治疗进展

Advances in the treatment of advanced melanoma with NRAS gene mutation

DOI：10.19401/j.cnki.1007-3639.2023.10.006

摘要

Abstract

关键词

Keywords

references